Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 178,000 |
Reported balance
After 2024-01-02 transaction · row 1
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 178,000 · Balance 178,000 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2034-01-01 | Direct | 228,000 |
Reported balance
After 2024-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-02 · Grant · Acquired 228,000 · Balance 228,000 F2: This award will vest in 36 equal monthly installments, so that it shall be fully vested on January 2, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027.
F2: This award will vest in 36 equal monthly installments, so that it shall be fully vested on January 2, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 22:07 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 228,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001453687-24-000024 · wk-form4_1704406012.xml · derivative · entry 2 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Stock · 228,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on January 2, 2027. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:07 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 178,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-24-000024 · wk-form4_1704406012.xml · nonDerivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,000 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | $0.93 Strike: $1.13 | $69,750.00 |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 7 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F7 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 6 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F6 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F6 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $4.01 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 5 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F5 · price: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. F5 · derivative.exercise_date: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 4 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F4 · price: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. F4 · derivative.exercise_date: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 3 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F3 · price: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. F3 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $12.75 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 2 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F2 · price: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:17 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,410 | Not disclosed Strike: $17.47 | Not disclosed |
DisclosureSEC source: 0001453687-23-000084 · wk-form4_1700086654.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F1 · price: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F1 · derivative.exercise_date: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:00 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000017 · wf-form4_167286958364872.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:35 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001453687-22-000022 · wf-form4_164141848053037.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 3, 2023. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001453687-21-000047 · wf-form4_161731631340894.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-29 F1 · derivative.exercise_date: This option vests in full on March 30, 2022. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:47 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000078 · wf-form4_159294523160862.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option vests in full on the earlier of June 19, 2021 or the day immediately prior to the company's 2021 annual meeting of stockholders. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 20:22 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001453687-19-000073 · wf-form4_156088930979080.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option vests in full on the earlier of June 14, 2020 or the day immediately prior to the company's 2020 annual meeting of stockholders. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 23:02 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001638599-18-000672 · doc4_5486.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option vests in full on the earlier of June 15, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 20:42 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 6,410 | $0.00 Strike: $17.47 | $0.00 |
DisclosureSEC source: 0001638599-17-000639 · doc4_4807.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,410 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.